Insider · CIK 0002114900
John Charles Thomas
Files at KRYS (Krystal Biotech, Inc.). First filing May 27, 2026, latest Jun 26, 2026.
In brief
John Charles Thomas files SEC Form 4 as officer at KRYS (Krystal Biotech, Inc.). Since May 27, 2026, John Charles Thomas has reported 0 open-market buys worth $0 and 2 open-market sells worth $541k, the latest filed on Jun 26, 2026.
A track record needs three past buys with six months of prices behind them; John Charles Thomas has 0, so none is measured yet.
The newest scored trade: sold $347k of KRYS on Jun 25, 2026, filed Jun 26, 2026, scored 15 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $541k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
KRYS: Krystal Biotech, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Krystal Biotech, Inc. | $347k 1,000 shares | -100% | +167% from low0% from high | |
| 42Moderate | Krystal Biotech, Inc. | $194k 642 shares | -100% | +145% from low-4% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 25, 2026 | KRYS Krystal Biotech, Inc. | 1,000 0.00% of outstanding | $347k | Jun 25, 2026 | $194k |
| May 26, 2026 | KRYS Krystal Biotech, Inc. | 642 0.00% of outstanding | $194k | May 26, 2026 | none |
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | KRYS Krystal Biotech, Inc. | MOption exercise Common Stock10b5-1 | +1,000 | $179.25 | $179k | 1,000 | Jun 26, 2026 |
| Jun 25, 2026 | KRYS Krystal Biotech, Inc. | SOpen-market sale Common Stock10b5-1 | -1,000 | $347.27 | $347k | 0 | Jun 26, 2026 |
| Jun 25, 2026 | KRYS Krystal Biotech, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,000 | $0.00 | $0 | 6,500 | Jun 26, 2026 |
| May 26, 2026 | KRYS Krystal Biotech, Inc. | SOpen-market sale Common Stock10b5-1 | -642 | $302.03 | $194k | 0 | May 27, 2026 |
Questions about John Charles Thomas
Answered from the filings on this page, as of the latest one.
Is John Charles Thomas buying or selling?
In the last 12 months John Charles Thomas reported 0 open-market buys worth $0 and 2 open-market sells worth $541k on SEC Form 4; the latest was sold $347k of KRYS on Jun 25, 2026. Grants, option exercises and tax withholding are not counted.
How did John Charles Thomas's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Charles Thomas has 0.
Where does John Charles Thomas file Form 4?
John Charles Thomas has filed Form 4 at KRYS (Krystal Biotech, Inc.) as EVP, General Counsel. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.